Read by QxMD icon Read

Pharmacotherapy for personality disorder

Bethany L Stangl, Vatsalya Vatsalya, Molly R Zametkin, Megan E Cooke, Martin H Plawecki, Sean O'Connor, Vijay A Ramchandani
BACKGROUND: Self-administration is a hallmark of all addictive drugs, including alcohol. Human laboratory models of alcohol self-administration have characterized alcohol-seeking behavior, and served as surrogate measures of the effectiveness of pharmacotherapies for alcohol use disorders. Intravenous alcohol self-administration (IV-ASA) is a novel method that assess alcohol exposure driven primarily by the pharmacological response to alcohol, and may have utility in characterizing unique behavioral and personality correlates of alcohol-seeking and consumption...
October 14, 2016: International Journal of Neuropsychopharmacology
Roy H Perlis
Effectiveness studies and analyses of naturalistic cohorts demonstrate that many patients with major depressive disorder do not experience symptomatic remission with antidepressant treatments. In an effort to better match patients with effective treatments, numerous investigations of predictors or moderators of treatment response have been reported over the past five decades, including clinical features as well as biological measures. However, none of these have entered routine clinical practice; instead, clinicians typically personalize treatment on the basis of patient preferences as well as their own...
October 2016: World Psychiatry: Official Journal of the World Psychiatric Association (WPA)
Emily C Williams, Jessica P Young, Carol E Achtmeyer, Christian S Hendershot
BACKGROUND: Efforts to identify genetic moderators of pharmacotherapy response have generated interest in clinical applications of pharmacogenetic tests in alcohol use disorder (AUD) treatment. To date, no research on providers' interest in using pharmacogenetic tests in the context of AUD treatment has been reported. We conducted qualitative interviews with primary care providers from 5 clinics in the Veterans Health Administration (VA) to assess their interest in using a hypothetical genetic test to inform treatment of AUD with pharmacotherapy...
November 2016: Journal of Substance Abuse Treatment
Enrico Paolini, Francesca Alice Fiore Mezzetti, Francesca Pierri, Patrizia Moretti
OBJECTIVE: Borderline personality disorder (BPD) is a high prevalence personality disorder. Pharmacotherapy is commonly used, however, a minority of studies investigated patterns of prescription for BPD, particularly in inpatients unit. We aimed to describe the clinical features and the prescribing practice for BPD patients, and to investigate the possible advantages of a single class of medications or of combined drug treatments in terms of length of stay in hospital. METHODS: This is a retrospective observational study evaluating 109 BPD inpatients from June 2011 to June 2013...
September 27, 2016: International Journal of Psychiatry in Clinical Practice
Alex H S Harris, Thomas Bowe, Hildi Hagedorn, Andrea Nevedal, Andrea K Finlay, Risha Gidwani, Craig Rosen, Chad Kay, Melissa Christopher
BACKGROUND: Active consideration of effective medications to treat alcohol use disorder (AUD) is a consensus standard of care, yet knowledge and use of these medications are very low across diverse settings. This study evaluated the overall effectiveness a multifaceted academic detailing program to address this persistent quality problem in the US Veterans Health Administration (VHA), as well as the context and process factors that explained variation in effectiveness across sites. METHODS: An interrupted time series design, analyzed with mixed-effects segmented logistic regression, was used to evaluate changes in level and rate of change in the monthly percent of patients with a clinically documented AUD who received naltrexone, acamprosate, disulfiram, or topiramate...
September 15, 2016: Addiction Science & Clinical Practice
Dan V Iosifescu, Robert J Neborsky, Robert J Valuck
PURPOSE: This study aims to determine whether Psychiatric Electroencephalography Evaluation Registry (PEER) Interactive (an objective, adjunctive tool based on a comparison of a quantitative electroencephalogram to an existing registry of patient outcomes) is more effective than the current standard of care in treatment of subjects suffering from depression. PATIENTS AND METHODS: This is an interim report of an ongoing, 2-year prospective, randomized, double blind, controlled study to evaluate PEER Interactive in guiding medication selection in subjects with a primary diagnosis of depression vs standard treatment...
2016: Neuropsychiatric Disease and Treatment
Kelly E Dunn, Joseph A Harrison, Jeannie-Marie Leoutsakos, Dingfen Han, Eric C Strain
AIMS: Neither the predictive value of early continuous abstinence in alcohol use disorder (AUD) or the point at which this effect may emerge has been evaluated. This analysis of the Combined Pharmacotherapies and Behavioral Interventions (COMBINE) clinical trial evaluated whether abstinence early in treatment was a predictor of longer term abstinence. METHODS: Participants who stated a goal of total abstinence (N = 954) were dichotomized into Early Abstainer vs...
August 27, 2016: Alcohol and Alcoholism: International Journal of the Medical Council on Alcoholism
Mark Zimmerman, Carolina Guzman Holst, Heather L Clark, Matthew Multach, Emily Walsh, Lia K Rosenstein, Douglas Gazarian
BACKGROUND: Concerns about the generalizability of pharmacotherapy efficacy trials to "real-world" patients have been raised for more than 40 years. Almost all of this literature has focused on treatment studies of major depressive disorder (MDD). OBJECTIVE: The aim of the study was to review the psychiatric inclusion and exclusion criteria used in placebo-controlled trials that assessed the efficacy of medications for bipolar depression (bipolar disorder efficacy trials [BDETs]) and compare the criteria used in BDETs with those used in efficacy trials of antidepressants to treat MDD (antidepressant efficacy trials [AETs])...
August 19, 2016: CNS Drugs
Daniel J Sadowski, Michael J Butcher, Tobias S Köhler
INTRODUCTION: Delayed ejaculation (DE) is a poorly defined disorder that entails the delay or absence of orgasm that results in personal distress. Numerous causes of DE exist, and management must be tailored to the specific etiology to maximize treatment success. Management strategies include psychological and sexual therapy, pharmacotherapy, and penile vibratory stimulation. AIM: This article intends to review the pathophysiology and treatment options for DE discussed in the literature to date...
April 2016: Sexual Medicine Reviews
Marianna Mazza, Giuseppe Marano, Luigi Janiri
No abstract text is available yet for this article.
October 2016: Expert Opinion on Pharmacotherapy
Eva Ceskova
No abstract text is available yet for this article.
October 2016: Expert Opinion on Pharmacotherapy
Miroslav Hajda, Jan Prasko, Klara Latalova, Radovan Hruby, Marie Ociskova, Michaela Holubova, Dana Kamaradova, Barbora Mainerova
BACKGROUND: Bipolar disorder (BD) is a serious mental illness with adverse impact on the lives of the patients and their caregivers. BD is associated with many limitations in personal and interpersonal functioning and restricts the patients' ability to use their potential capabilities fully. Bipolar patients long to live meaningful lives, but this goal is hard to achieve for those with poor insight. With progress and humanization of society, the issue of patients' needs became an important topic...
2016: Neuropsychiatric Disease and Treatment
Marie Ociskova, Jan Prasko, Klara Latalova, Dana Kamaradova, Ales Grambal
BACKGROUND: Anxiety disorders are a group of various mental syndromes that have been related with generally poor treatment response. Several psychological factors may improve or hinder treatment effectiveness. Hope has a direct impact on the effectiveness of psychotherapy. Also, dissociation is a significant factor influencing treatment efficiency in this group of disorders. Development of self-stigma could decrease treatment effectiveness, as well as several temperamental and character traits...
2016: Neuropsychiatric Disease and Treatment
Stephen F Smagula, Meredith L Wallace, Stewart J Anderson, Jordan F Karp, Eric J Lenze, Benoit H Mulsant, Meryl A Butters, Daniel M Blumberger, Breno S Diniz, Francis E Lotrich, Mary Amanda Dew, Charles F Reynolds
Personalizing treatment for late-life depression requires identifying and integrating information from multiple factors that influence treatment efficacy (moderators). We performed exploratory moderator analyses using data from a multi-site, randomized, placebo-controlled, double-blind trial of aripiprazole augmentation. Patients (n = 159) aged ≥60 years had major depressive disorder that failed to remit with venlafaxine monotherapy. We examined effect sizes of 39 potential moderators of aripiprazole (vs...
October 2016: Journal of Psychiatric Research
Carlos De Las Cuevas, Ramsés Marrero, Casimiro Cabrera
PURPOSE: To determine the level of treatment-related decisional conflict in patients with emotional disorders and to establish its relationship with sociodemographic and clinical variables. METHODS: We conducted a cross-sectional survey on a convenience sample of 321 consecutive psychiatric outpatients with emotional disorders. All patients completed self-report questionnaires assessing sociodemographic and clinical variables, patients' preference of participation in decision making, perceived decisional conflict about treatment, adherence to prescribed treatment, and satisfaction with the psychiatric care provided...
2016: Patient Preference and Adherence
Apurba Barman, Ahana Chatterjee, Rohit Bhide
Traumatic brain injury (TBI) is among the significant causes of morbidity and mortality in the present world. Around 1.6 million persons sustain TBI, whereas 200,000 die annually in India, thus highlighting the rising need for appropriate cognitive rehabilitation strategies. This literature review assesses the current knowledge of various cognitive rehabilitation training strategies. The entire spectrum of TBI severity; mild to severe, is associated with cognitive deficits of varying degree. Cognitive insufficiency is more prevalent and longer lasting in TBI persons than in the general population...
May 2016: Indian Journal of Psychological Medicine
D Fraguas, C M Díaz-Caneja, M W State, M C O'Donovan, R E Gur, C Arango
Personalized or precision medicine is predicated on the assumption that the average response to treatment is not necessarily representative of the response of each individual. A commitment to personalized medicine demands an effort to bring evidence-based medicine and personalized medicine closer together. The use of relatively homogeneous groups, defined using a priori criteria, may constitute a promising initial step for developing more accurate risk-prediction models with which to advance the development of personalized evidence-based medicine approaches to heterogeneous syndromes such as schizophrenia...
June 23, 2016: Psychological Medicine
Jillian H Broadbear, Julian Nesci, Rosemary Thomas, Katherine Thompson, Josephine Beatson, Sathya Rao
OBJECTIVE: Residential patients diagnosed with borderline personality disorder were evaluated to determine whether borderline personality disorder-focused psychotherapy reduced prescribing, personality disorder and co-morbid symptom severity. METHOD: Psychotropic prescriptions were measured at admission, discharge and 1 year later in 74 female participants with one or more personality disorder diagnosis and co-morbid mood disorders. Changes in pharmacotherapy were examined in the context of improvements in borderline personality disorder and/or co-morbid disorder symptom severity...
June 20, 2016: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
Hannah K Knudsen
BACKGROUND: The high prevalence of smoking among individuals receiving treatment for substance use disorder (SUD) has led to repeated calls for integrating smoking cessation treatment into these settings. OBJECTIVES: This review summarizes key findings from the research on the implementation of smoking cessation in SUD treatment. METHODS: PubMed searches of articles published from 2000 to 2015 yielded 48 empirical studies that focused on the delivery of smoking cessation in the US specialty SUD treatment settings in which organizations and counselors were the unit of analysis...
June 17, 2016: American Journal of Drug and Alcohol Abuse
Yannick Vermeiren, Jana Janssens, Tony Aerts, Jean-Jacques Martin, Anne Sieben, Debby Van Dam, Peter P De Deyn
Routinely prescribed psychoactive drugs in behavioral variant frontotemporal dementia (FTD) for improvement of (non)cognitive symptoms are primarily based on monoamine replacement or augmentation strategies. These were, however, initially intended to symptomatically treat other degenerative, behavioral, or personality disorders, and thus lack disease specificity. Moreover, current knowledge on brain monoaminergic neurotransmitter deficiencies in this presenile disorder is scarce, particularly with reference to changes in Alzheimer's disease (AD)...
June 15, 2016: Journal of Alzheimer's Disease: JAD
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"